Thor Medical ASA (FRA:8NN) EBITDA Margin %: -4,820.59% (As of Dec. 2025)


FRA:8NN Thor Medical ASA FRA:8NN
21 GF Score
Price €0.39
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA EBITDA Margin %?

Thor Medical ASA FRA:8NN +1.71% 21 EBITDA Margin % is -4,820.59% as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Thor Medical ASA ranks worse than 92.9% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Thor Medical ASA's EBITDA for the six months ended in Dec. 2025 was €-1.64 Mil. Thor Medical ASA's Revenue for the six months ended in Dec. 2025 was €0.03 Mil. Therefore, Thor Medical ASA's EBITDA margin for the quarter that ended in Dec. 2025 was -4,820.59%.

Thor Medical ASA  (FRA:8NN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Thor Medical ASA EBITDA Margin % Related Terms

Thor Medical ASA EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Thor Medical ASA's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thor Medical ASA EBITDA Margin % Chart

Thor Medical ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -9,305.41

Thor Medical ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -20,511.11 -4,820.59

FRA:8NN vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Thor Medical ASA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thor Medical ASA EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's EBITDA Margin % falls into.


FRA:8NN
21GF Score
Thor Medical ASA FRA:8NN
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thor Medical ASA EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Thor Medical ASA's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.443/0.037
=-9,305.41 %

Thor Medical ASA's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.639/0.034
=-4,820.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -4,820.59% mean?
Thor Medical ASA (FRA:8NN) has a EBITDA Margin % of -4,820.59% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thor Medical ASA and its competitors. According to the industry distribution chart, Thor Medical ASA ranks #877 out of 944 companies in the Biotechnology industry, placing it in the top 92.9%.
Is Thor Medical ASA's EBITDA Margin % too high?
Thor Medical ASA's current EBITDA Margin % is -4,820.59%. Based on the distribution chart, Thor Medical ASA ranks #877 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Thor Medical ASA has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #877 out of 944 companies for EBITDA Margin %. This places Thor Medical ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current EBITDA Margin % is -4,820.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current EBITDA Margin % of -4,820.59%. The current EBITDA Margin % is -4,820.59%. Thor Medical ASA's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current EBITDA Margin % is -4,820.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thor Medical ASA Business Description

Other Exchanges TRMED:Norway0R6Y:UK
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
21GF Score

Get the complete analysis for FRA:8NN

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price